Latest news
What’s the difference between a heart attack and cardiac arrest?
Both are life-threatening heart-health emergencies, but they are two distinct conditions with different causes and treatment. Here’s what a cardiologist wants you to know.
How Johnson & Johnson is fighting counterfeit medical products
Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.
Photo courtesy of GBP LATAM team
More from Johnson & Johnson
Diversity in the OR: 3 barrier-breaking female surgeons share their stories
Only one in 10 orthopedic surgeons in the U.S. are women. Learn how Johnson & Johnson is working to change that stat.
What you need to know about Johnson & Johnson’s 2023 transparency report
The annual report has just been released—here are key takeaways that showcase the company’s commitment to creating a more sustainable, equitable and innovative healthcare system.
Meet two brothers who are revolutionizing the way scientists develop treatments for cancer
Justin and Colin Farlow share how their next-generation cell and gene therapies are helping Johnson & Johnson in its quest to get in front of cancer.
What to know about We All Belong: 2023 DEI Impact Review
The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.
What are cataracts?
If you can’t read a screen without jacking up the brightness level or if night driving leaves you seeing fuzzy halos around traffic lights, you may among the 20 million U.S. adults who develops a cataract—the most common cause of vision loss worldwide. Luckily a simple surgical procedure can have you viewing the world in crisp, bright color again. Here’s what to know about cataract symptoms and removal.
Press releases
Johnson & Johnson Completes Acquisition of V-Wave
Adds V-Wave’s Novel and Minimally Invasive Ventura® Interatrial Shunt to the Johnson & Johnson MedTech Portfolio Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular Disease
Johnson & Johnson Celebrates Innovation in Regulated RNA and Protein Degradation with 2024 Dr. Paul Janssen Award for Biomedical Research
Lynne Maquat, Ph.D., and Alexander Varshavsky, Ph.D., to receive 2024 Dr. Paul Janssen Award for their fundamental discoveries about regulated degradation of RNA and proteins.
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
New Brunswick, N.J., October 4th, 2024 – Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12th, at the InterContinental Boston in Boston, MA. Biljana Naumovic, President, Solid Tumor, U.S. Oncology and Mark Wildgust, Vice President, Global Medical Affairs Oncology, will represent the Company in a session scheduled at 10:30 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast.
Johnson & Johnson to Discontinue Phase 2 Field Study Evaluating Investigational Antiviral for the Prevention of Dengue
No safety issues identified to date
Johnson & Johnson showcases innovation and commitment to people living with gMG, presenting 25 abstracts at AANEM Annual Meeting and MGFA Scientific Session
Johnson & Johnson (NYSE: JNJ) announced today that 25 abstracts featuring robust research to understand unmet needs in generalized myasthenia gravis (gMG) and evaluate nipocalimab as a potential advanced treatment option will be presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session from October 15-18, 2024 in Savannah, Georgia.
